Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
39.49
+0.18 (0.45%)
Feb 5, 2025, 1:03 PM EST - Market open
Biohaven Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
239
Market Cap
3.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBHVN News
- 23 days ago - Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generation Potential Therapy for IgA Nephropathy - PRNewsWire
- 4 weeks ago - Biohaven to Present at the 43rd Annual J.P. Morgan Healthcare Conference - PRNewsWire
- 7 weeks ago - Biohaven Advances in Immunotherapy: Significant IgG Reduction Achieved with BHV-1300, Gains Analyst Approval - Benzinga
- 7 weeks ago - Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PRNewsWire
- 2 months ago - Biohaven Presents New Data with BHV-7000 Once-Daily Extended-Release Formulation Demonstrating Excellent Safety Profile and Nonclinical Data Updates at American Epilepsy Society 2024 Annual Meeting - PRNewsWire
- 2 months ago - Biohaven's Revenue Path: SCA And Obesity Therapies - Seeking Alpha
- 2 months ago - Cassava Sciences, Biohaven And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
- 2 months ago - Biohaven's spinal muscular atrophy drug fails to meet main goal in study - Reuters